Over $3.7M awarded to McGill researchers studying neurodevelopmental disorders

Prime Minister Stephen Harper announces funding from Government of Canada, The Azrieli Foundation and Brain Canada

MONTREAL, May 1, 2014 /CNW Telbec/ - Internationally renowned McGill University researchers Alan Evans and Nahum Sonenberg are among the recipients of new funding for research into neurological disorders announced today by Prime Minister Stephen Harper at an event in Montreal.

Dr. Evans and Dr. Sonenberg will receive over $3.7 million from the Azrieli Neurodevelopmental Research Program, funded by The Azrieli Foundation, the Brain Canada Foundation and the Government of Canada through the Canada Brain Research Fund. The Azrieli Neurodevelopmental Research Program focuses on autism spectrum disorders (ASD) and fragile-x syndrome (FXS), with a goal to develop new diagnostics, treatment and prevention strategies for these disorders.

"On behalf of the McGill community, I want to thank the Government of Canada, The Azrieli Foundation and Brain Canada for supporting cutting-edge research on neurodevelopmental disorders. This new investment will support the overall care and well-being of Canadians through improved understanding and treatment of these mental and neurological disorders," said Prof. Suzanne Fortier, Principal and Vice-Chancellor.  "We are very proud that Dr. Evans and Dr. Sonenberg's combined expertise in brain imaging, network analysis and translational control mechanisms has been recognized through this important investment."  

To read the full release

SOURCE: McGill University

For further information: Julie Fortier, Associate Director, Media Relations, McGill University, 514-398-6751, julie.c.fortier@mcgill.ca


Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .


Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.


Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.